EurekAlert! -
10 Apr 2020 06:00
(University of Pennsylvania School of Medicine) A prospective 'PARP inhibitor' drug that has struggled to show effectiveness in clinical trials against cancers can be structurally modified to greatly increase its power to kill tumor cells, researchers from Penn Medicine report this week in Science.
Share this Article
Comment on this Article
Please to comment